| Jerrod Cole Weems, | |
|
305 Langdon St, Somerset, KY 42503-2750 | |
| (606) 678-3288 | |
| Not Available |
| Full Name | Jerrod Cole Weems |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 305 Langdon St, Somerset, Kentucky |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912538133 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 3014260 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morristown Hamblen Hospital Association | Morristown, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hamblen Anesthesia Pc | 3476520875 | 11 |
News Archive
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),
A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3's scaffolding ability, independent of cell death.
A study presented today at the European Congress on Osteoporosis and Osteoarthritis currently taking place in Valencia, Spain has found that the initial quality of life loss following an osteoporotic fracture is substantial, especially with regard to hip and vertebral fractures. The study found differences in quality of life loss between countries after correcting for other explanatory variables.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.
› Verified 4 days ago
| Entity Name | Hamblen Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821007485 PECOS PAC ID: 3476520875 Enrollment ID: O20040915000212 |
News Archive
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),
A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3's scaffolding ability, independent of cell death.
A study presented today at the European Congress on Osteoporosis and Osteoarthritis currently taking place in Valencia, Spain has found that the initial quality of life loss following an osteoporotic fracture is substantial, especially with regard to hip and vertebral fractures. The study found differences in quality of life loss between countries after correcting for other explanatory variables.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jerrod Cole Weems, 305 Langdon St, Somerset, KY 42503-2750 Ph: () - | Jerrod Cole Weems, 305 Langdon St, Somerset, KY 42503-2750 Ph: (606) 678-3288 |
News Archive
A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.
Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),
A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3's scaffolding ability, independent of cell death.
A study presented today at the European Congress on Osteoporosis and Osteoarthritis currently taking place in Valencia, Spain has found that the initial quality of life loss following an osteoporotic fracture is substantial, especially with regard to hip and vertebral fractures. The study found differences in quality of life loss between countries after correcting for other explanatory variables.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.
› Verified 4 days ago
Justin Timothy Pate, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-678-3288 | |
Benjamin Thomas Kabel, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-678-7441 | |
Daniel G. Patton, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 | |
Chelsey Herzig Donohue, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 108 Southridge Dr, Somerset, KY 42503 Phone: 218-349-7479 | |
Lucas Daniel Holcomb, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 | |
Kimberly Brady Sexton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-678-3288 Fax: 606-679-3108 | |
Eric M Toohey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 |